travel/residence history of communities with reported cases within 14 days before trial; history of exposure to novel coronavirus infection (nucleic acid positive) within 14 days prior to the trial; exposed to patients with fever or respiratory symptoms from communities with reported cases within 14 days prior to the trial; two or more cases of fever and/or respiratory symptoms in a small area such as home, office, school and class within 14 days prior to the trial; history of sars-cov-2 infection; history of asthma, history of allergy to vaccines or vaccine ingredients, and severe adverse reactions to vaccines, such as urticaria, dyspnea, and angioneurotic edema; congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.; autoimmune disease or immunodeficiency/immunosuppression; patients with serious chronic diseases, serious cardiovascular diseases, uncontrolled hypertension and diabetes, liver and kidney diseases, malignant tumors, etc.; serious neurological disorder (epilepsy, convulsions or convulsions) or psychosis; history of thyroid disease or thyroidectomy, absence of spleen, functional absence of spleen, and absence of spleen or splenectomy caused by any circumstance; coagulation dysfunction (such as coagulation factor deficiency, coagulation disease, platelet abnormality) or obvious bruising or coagulation disorder diagnosed by doctors; immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding corticosteroid spray therapy for allergic rhinitis, and surface corticosteroid therapy for acute non-complicated dermatitis) in the past 6 months; long history of alcohol or drug abuse; received blood products within 3 months prior to receiving the vaccine; received other research drugs within 30 days prior to receiving the vaccine; received live attenuated vaccine within 14 days prior to receiving the vaccine; received subunit or inactivated vaccine within 7 days prior to receiving the vaccine; onset of various acute or chronic diseases within 7 days prior to the study; axillary temperature of >37.0℃ before inoculation of the vaccine; those who are already pregnant (including a positive urine pregnancy test) or are breastfeeding, planning to become pregnant within 2 months; in the opinion of the investigator, the participants had any other factors that made them unsuitable to participate in the clinical trial.

travel/residence history of communities with reported cases within 14 days before trial; history of exposure to novel coronavirus infection (nucleic acid positive) within 14 days prior to the trial; exposed to patients with fever or respiratory symptoms from communities with reported cases within 14 days prior to the trial; two or more cases of fever and/or respiratory symptoms in a small area such as home, office, school and class within 14 days prior to the trial; history of sars-cov-2 infection; history of asthma, history of allergy to vaccines or vaccine ingredients, and severe adverse reactions to vaccines, such as urticaria, dyspnea, and angioneurotic edema; congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.; autoimmune disease or immunodeficiency/immunosuppression; patients with serious chronic diseases, serious cardiovascular diseases, uncontrolled hypertension and diabetes, liver and kidney diseases, malignant tumors, etc.; serious neurological disorder (epilepsy, convulsions or convulsions) or psychosis; history of thyroid disease or thyroidectomy, absence of spleen, functional absence of spleen, and absence of spleen or splenectomy caused by any circumstance; coagulation dysfunction (such as coagulation factor deficiency, coagulation disease, platelet abnormality) or obvious bruising or coagulation disorder diagnosed by doctors; immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding corticosteroid spray therapy for allergic rhinitis, and surface corticosteroid therapy for acute non-complicated dermatitis) in the past 6 months; long history of alcohol or drug abuse; received blood products within 3 months prior to receiving the vaccine; received other research drugs within 30 days prior to receiving the vaccine; received live attenuated vaccine within 14 days prior to receiving the vaccine; received subunit or inactivated vaccine within 7 days prior to receiving the vaccine; onset of various acute or chronic diseases within 7 days prior to the study; axillary temperature of >37.0℃ before inoculation of the vaccine; those who are already pregnant (including a positive urine pregnancy test) or are breastfeeding, planning to become pregnant within 2 months; in the opinion of the investigator, the participants had any other factors that made them unsuitable to participate in the clinical trial.

1. travel/residence history of communities with reported cases within 14 days before trial; 2. history of exposure to novel coronavirus infection (nucleic acid positive) within 14 days prior to the trial; 3. exposed to patients with fever or respiratory symptoms from communities with reported cases within 14 days prior to the trial; 4. two or more cases of fever and/or respiratory symptoms in a small area such as home, office, school and class within 14 days prior to the trial; 5. history of sars-cov-2 infection; 6. history of asthma, history of allergy to vaccines or vaccine ingredients, and severe adverse reactions to vaccines, such as urticaria, dyspnea, and angioneurotic edema; 7. congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.; 8. autoimmune disease or immunodeficiency/immunosuppression; 9. patients with serious chronic diseases, serious cardiovascular diseases, uncontrolled hypertension and diabetes, liver and kidney diseases, malignant tumors, etc.; 10. serious neurological disorder (epilepsy, convulsions or convulsions) or psychosis; 11. history of thyroid disease or thyroidectomy, absence of spleen, functional absence of spleen, and absence of spleen or splenectomy caused by any circumstance; 12. coagulation dysfunction (such as coagulation factor deficiency, coagulation disease, platelet abnormality) or obvious bruising or coagulation disorder diagnosed by doctors; 13. immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding corticosteroid spray therapy for allergic rhinitis, and surface corticosteroid therapy for acute non-complicated dermatitis) in the past 6 months; 14. long history of alcohol or drug abuse; 15. received blood products within 3 months prior to receiving the vaccine; 16. received other research drugs within 30 days prior to receiving the vaccine; 17. received live attenuated vaccine within 14 days prior to receiving the vaccine; 18. received subunit or inactivated vaccine within 7 days prior to receiving the vaccine; 19. onset of various acute or chronic diseases within 7 days prior to the study; 20. axillary temperature of >37.0℃ before inoculation of the vaccine; 21. those who are already pregnant (including a positive urine pregnancy test) or are breastfeeding, planning to become pregnant within 2 months; 22. in the opinion of the investigator, the participants had any other factors that made them unsuitable to participate in the clinical trial.

1. travel/residence history of communities with reported cases within 14 days before trial; 2. history of exposure to novel coronavirus infection (nucleic acid positive) within 14 days prior to the trial; 3. exposed to patients with fever or respiratory symptoms from communities with reported cases within 14 days prior to the trial; 4. two or more cases of fever and/or respiratory symptoms in a small area such as home, office, school and class within 14 days prior to the trial; 5. history of sars-cov-2 infection; 6. history of asthma, history of allergy to vaccines or vaccine ingredients, and severe adverse reactions to vaccines, such as urticaria, dyspnea, and angioneurotic edema; 7. congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.; 8. autoimmune disease or immunodeficiency/immunosuppression; 9. patients with serious chronic diseases, serious cardiovascular diseases, uncontrolled hypertension and diabetes, liver and kidney diseases, malignant tumors, etc.; 10. serious neurological disorder (epilepsy, convulsions or convulsions) or psychosis; 11. history of thyroid disease or thyroidectomy, absence of spleen, functional absence of spleen, and absence of spleen or splenectomy caused by any circumstance; 12. coagulation dysfunction (such as coagulation factor deficiency, coagulation disease, platelet abnormality) or obvious bruising or coagulation disorder diagnosed by doctors; 13. immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding corticosteroid spray therapy for allergic rhinitis, and surface corticosteroid therapy for acute non-complicated dermatitis) in the past 6 months; 14. long history of alcohol or drug abuse; 15. received blood products within 3 months prior to receiving the vaccine; 16. received other research drugs within 30 days prior to receiving the vaccine; 17. received live attenuated vaccine within 14 days prior to receiving the vaccine; 18. received subunit or inactivated vaccine within 7 days prior to receiving the vaccine; 19. onset of various acute or chronic diseases within 7 days prior to the study; 20. axillary temperature of >37.0℃ before inoculation of the vaccine; 21. those who are already pregnant (including a positive urine pregnancy test) or are breastfeeding, planning to become pregnant within 2 months; 22. in the opinion of the investigator, the participants had any other factors that made them unsuitable to participate in the clinical trial.